SUPN — Supernus Pharmaceuticals, Inc.
Is SUPN overbought or oversold? Here is the current MarketMoodz read.
Supernus Pharmaceuticals, Inc. (SUPN) currently reads Neutral on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Drug Manufacturers - Specialty & Generic) last closed at $28.83. The rating moved from Oversold to Neutral on November 13, 2026.
- Public ratingNeutral (as of November 17, 2026)
- Last close$28.83
- Last changeMoved from Oversold to Neutral on November 13, 2026
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
AI analysis
Supernus Pharmaceuticals, Inc. (SUPN) is a CNS-focused specialty pharmaceutical company with revenue driven by a limited portfolio led by Qelbree. The company benefits from established commercial infrastructure and upside potential from label expansion, pediatric indications and pipeline readouts, while constrained by revenue concentration and the need for continued payer acceptance. Near-term market conditions are cautious with defensive flows that may limit multiple expansion for mid-cap specialty pharmas. Key catalysts to monitor are quarterly commercial performance, any regulatory or payer developments, clinical readouts, and business development activity. Base-case outlook is steady top-line growth with episodic volatility tied to clinical and payer news; downside scenarios include adverse trial results or accelerated payer reimbursement tightening.
Key factors
- Supernus Pharmaceuticals, Inc. (SUPN) has a concentrated CNS product portfolio with Qelbree (viloxazine) as a key revenue driver; continued commercial adoption and label expansion are primary growth levers.
- Stable near-term revenue visibility from established products combined with ongoing R&D/clinical programs that could create medium-term upside if positive readouts occur.
- Solid commercial infrastructure and specialty-channel access that supports prescriptions for ADHD and other CNS indications.
- Defensive market flows into large-cap pharma and uncertainty around macro/rate expectations reduce upside for mid-cap specialty names in the near term.
- Reasonable balance-sheet and cash generation to support operations and selective business development, but limited ability to compete with deep-pocketed large pharmas on broad label expansion without partners.
- Potential M&A or partnership interest from larger pharma could be a catalyst, but outcome and timing are uncertain.
Risks
- Medicare Advantage regulatory tightening (RADV / program integrity) and broader payer pressure could constrain pricing or reimbursement trends for therapies that rely on insurance coverage expansion.
- Revenue concentration risk: dependence on a small number of marketed products means clinical setbacks, safety signals or slower uptake could materially impact results.
- Competitive pressure from branded competitors, generics, or new entrants (including novel mechanisms for ADHD/neurology) could limit market share and pricing power.
- Clinical development risk: negative or delayed trial data for pipeline candidates would reduce growth prospects and investor sentiment.
- Commercial execution risk in specialty channels and potential supply/distribution disruptions.
- Valuation sensitivity to cyclical market sentiment and defensive flows to large-cap pharma could compress multiples for mid‑cap specialty names like SUPN.
See today's live rating, score and targets
Members see the live hourly rating for SUPN — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.